Pharmacovigilance in Cell and Gene Therapy: Evolving Challenges in Risk Management and Long-Term Follow-Up
Drug Safety · 2026-01 · 49 (1) · 27-53
DOI: 10.1007/s40264-025-01596-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Safety, online erschienen am 09.08.2025. Verfasst von Emile Youssef und 3 weiteren Autor:innen. Beteiligte Einrichtung: Kapadi, Inc., 9650 Strickland Road, Raleigh, NC, 27615, USA. emile.youssef@kapadi.com. Hauptthemen laut MEDLINE: Pharmacovigilance, Genetic Therapy, Risk Management, Cell- and Tissue-Based Therapy. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 220 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Kapadi, Inc., 9650 Strickland Road, Raleigh, NC, 27615, USA. emile.youssef@kapadi.com.
- Kapadi, Inc., 9650 Strickland Road, Raleigh, NC, 27615, USA.
ORCID-Profile: Emile Youssef
Zitieren
APA
Youssef, E., Weddle, K., Zimmerman, L., & Palmer, D. (2026). Pharmacovigilance in Cell and Gene Therapy: Evolving Challenges in Risk Management and Long-Term Follow-Up. Drug Safety, 49(1), 27-53. https://doi.org/10.1007/s40264-025-01596-9
Vancouver
Youssef E, Weddle K, Zimmerman L, Palmer D. Pharmacovigilance in Cell and Gene Therapy: Evolving Challenges in Risk Management and Long-Term Follow-Up. Drug Safety. 2026;49(1):27-53. doi:10.1007/s40264-025-01596-9
BibTeX
@article{Youssef2026,
author = {Youssef, Emile and Weddle, Kari and Zimmerman, Lisa and Palmer, Dannelle},
title = {Pharmacovigilance in Cell and Gene Therapy: Evolving Challenges in Risk Management and Long-Term Follow-Up},
journal = {Drug Safety},
year = {2026},
volume = {49},
number = {1},
pages = {27--53},
doi = {10.1007/s40264-025-01596-9}
}
EUVIMED